Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Cell Transfection System

August 26, 2010 9:42 am | Product Releases | Comments

Lonza’s 4D-Nucleofector System is lifting the Amaxa Nucleofector Technology to the next dimension. Lonza engineers and scientists have developed a system which is designed for maximum flexibility combined with advanced performance and convenience.

TOPICS:

Scientists Develop Atomic View of Key Genetic Processes

August 26, 2010 9:36 am | News | Comments

Using X-ray crystallography, Penn State researchers have built the first-ever image of a protein interacting with the nucleosome—DNA packed tightly into space-saving bundles organized around a protein core. The research is expected to aid future investigations into diseases such as cancer.

TOPICS:

Researchers Find New Mechanism for Making Memories

August 26, 2010 9:32 am | News | Comments

Scientists have discovered a mechanism that plays a critical role in the formation of long-term memory. The findings shed substantial new light on aspects of how memory is formed, and could lead to novel treatments for memory disorders.

TOPICS:
Advertisement

Frog Skin May Destroy Antibiotic-Resistant Germs

August 26, 2010 9:22 am | News | Comments

Kissing a frog won’t turn it into a prince — except in fairy tales ? but frogs may be hopping toward a real-world transformation into princely allies in humanity’s battle with antibiotic-resistant infections that threaten millions of people worldwide.

TOPICS:

More Problems At J & J Subsidiary

August 26, 2010 9:18 am | News | Comments

Johnson & Johnson's artificial joint business is recalling two hip replacement products, just two days after getting hit with a government warning that it is illegally marketing two other products. It is the 11th J&J recall since September.

TOPICS:

IDBS Acquires Quantrix

August 26, 2010 7:24 am | News | Comments

IDBS, a worldwide provider of data management and analytics solutions to healthcare organizations, announced that it has concluded an agreement to acquire Quantrix, a company that provides business modeling and analytics software and services.

TOPICS:

Judge Blocks Sanofi Injunction Request

August 26, 2010 7:20 am | News | Comments

Momenta Pharmaceuticals, Inc. announced that a judge has denied sanofi-aventis' request for a preliminary injunction directing the FDA to suspend and withdraw its approval of the ANDA filed by Momenta's partner, Sandoz, for a generic version of Lovenox.

TOPICS:

PROLOR Cleared for Phase 2 Trial

August 26, 2010 7:14 am | News | Comments

PROLOR Biotech, Inc. announced that it has received regulatory clearance from the U.S. Food and Drug Administration to conduct a Phase 2 clinical trial in the U.S. of its longer-acting version of human growth hormone, hGH-CTP.

TOPICS:
Advertisement

Daiichi Sankyo Files for Denosumab Approval

August 26, 2010 7:09 am | News | Comments

Daiichi Sankyo Company, Limited, announced that it has filed for approval in Japan to manufacture and market AMG 162 (denosumab), a gene recombinant drug for bone disorders stemming from bone metastases.

TOPICS:

FDA Approves Protocol for Phase 2 Trial

August 26, 2010 7:01 am | News | Comments

Chelsea Therapeutics International, Ltd. announced confirmation that the U.S. Food and Drug Administration has approved its proposed Phase 2 protocol for CH-4051 in rheumatoid arthritis. Patient screening is to begin next month and treatment starts in October.

TOPICS:

Afferent Drug Reduces Bladder Hyperactivity

August 26, 2010 6:55 am | News | Comments

Afferent Pharmaceuticals, a biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, announced results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

TOPICS:

Edge And SurModics Collaborate on TBI Treatment

August 26, 2010 6:43 am | News | Comments

According to the agreement, SurModics will develop Edge Therapeutics' lead candidate, Nimogel, a novel biodegradable, site-specific, sustained-release formulation for treatment of delayed complications of ruptured brain aneurysms or traumatic brain injury.

TOPICS:

Hybrid Multi-Mode Microplate Reader

August 25, 2010 8:35 am | Product Releases | Comments

BioTek, a market leader in hybrid microplate detection technology, has released its newest product, the Synergy H1 Hybrid Multi-Mode Microplate Reader.

TOPICS:

UV-Visible Spectrophotometer

August 25, 2010 8:31 am | Product Releases | Comments

Thermo Fisher Scientific Inc. announced the launch of its Evolution 200 series of next-generation UV-Visible spectrophotometers featuring new INSIGHT software with CUE (Customized User Environment) scripting capabilities.

TOPICS:

Sanger And Horizon Collaborate On Translational Genomics

August 25, 2010 8:21 am | News | Comments

Two Cambridge-based organisations, the Wellcome Trust’s Sanger Institute and Horizon Discovery, will collaborate to translate the abundance of new information on human genetic variation into more effective treatments for cancer.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading